Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

NICE recommends Novartis combo as first-ever BRAF-targeted therapy for advanced post-surgery melanoma

September 17, 2018
Sales and Marketing Cancer, NICE, Novartis, Tafinlar, mekinist, melanoma, pharma

NICE has taken the decision to recommend the first ever first BRAF-targeted therapy for use on the NHS in England …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week

September 14, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, FDA, NICE, Novo Nordisk, Spinraza, brexit, bristol myers squibb, top 10

With the Pharmafocus team having avoided hurricane Florence and finally arriving back in the UK just last night, after stopping …

News
14680814113_e81affc144_z_1

UK Health Secretary Matt Hancock rallies against ‘rip off’ pharma companies

September 11, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, Matt Hancock, NICE, Vertex, pharma, pricing

British Health Secretary Matt Hancock has said that pharmaceutical companies are trying to “rip off taxpayers” and that big business …

News

Protesters in Manchester call on NICE to approve Biogen’s $750,000 drug Spinraza

September 11, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Spinraza, approval, protest, sma

Protesters in Manchester have called on the National Institute of Health and Care Excellence (NICE), to overturn their rejection of …

News
opdivo_1_1

BMS’ Opdivo fails to win over NICE as adjuvant melanoma therapy

September 10, 2018
Sales and Marketing BMS, NHS, NICE, melanoma, opdivo, pharma

Bristol-Myers Squibb has failed to convince NICE to approve the use of its PD-1 inhibitor immunotherapy Opdivo (nivolumab) as an …

News

NICE rejects Roche’s Ocrevus in primary progressive multiple sclerosis

September 10, 2018
Sales and Marketing NICE, Ocrevus, Roche, UK, multiple sclerosis, pharma

Of the 100,000 MS patients in England, around one in eight have the primary progressive form (PPMS), which brings debilitating …

News
biogen_austria_238

NICE rejects Biogen’s spinal muscular dystrophy drug Spinraza after long delay

August 14, 2018
Manufacturing and Production, Sales and Marketing Biogen, NICE, Spinraza, UK, pharma, spinal muscular dystrophy

UK watchdog NICE has rejected Biogen’s spinal muscular dystrophy drug Spinraza (nusinersen) over cost concerns, denying patients the only available …

News
nhs_sign

NHS scraps restriction on availability of J&J’s Imbruvica in leukaemia patients

August 10, 2018
Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, NHS, NICE, UK, imbruvica, leukaemia, pharma

The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), …

News

NICE recommends Eli Lilly’s psoriatic arthritis drug

August 9, 2018
Research and Development, Sales and Marketing Eli Lilly, England, NICE, Wales, psoriatic arthritis

Eli Lilly have announced that the monoclonal antibody ixekizumab, has been recommended by NICE for use as a treatment option …

News

NICE recommends Pfizer’s Besponsa in rare leukaemia following review

August 9, 2018
Sales and Marketing NICE, Pfizer, leukaemia, pharma

Pfizer has revealed that NICE has finally decided to recommend its CD22-targeting monoclonal antibody Besponsa (inotuzumab ozogamicin) in the treatment …

News

NICE approves treatment for rare and deadly childhood cancer

July 11, 2018
Sales and Marketing Cancer, NICE, UK, neuroblastoma, pharma

NICE has recommended that monoclonal antibody dinutuximab beta be used in treating high-risk neuroblastoma – a rare and deadly form …

News

NICE calls to limit antibiotic use in COPD over antimicrobial resistance fears

July 10, 2018
Manufacturing and Production, Medical Communications, Research and Development COPD, NICE, antimicrobial resistance, chronic obstructive pulmonary disease, pharma

NICE have published a draft antimicrobial prescribing guide recommending that healthcare professionals should consider the risk of antimicrobial resistance when …

News
opdivo_1_1

NICE turns down BMS’ blockbuster Opdivo for urothelial carcinoma

July 5, 2018
Sales and Marketing BMS, Bristol-Myers Squibb, NICE, opdivo, pharma, urothelial carcinoma

Just in time for the NHS’ 70th birthday, UK watchdog NICE has announced that it has taken the decision to …

News

NICE turns down Roche’s Ocrevus in early primary progressive multiple sclerosis

June 29, 2018
Medical Communications, Sales and Marketing NICE, Ocrevus, Roche, pharma

Roche’s sometimes strained relationship with NICE continues as the health watchdog for England and Wales chose to reject the former’s …

News

Roche’s Alecensa secures NICE approval in NSCLC after topping Pfizer’s Xalkori

June 28, 2018
Sales and Marketing Alecensa, NICE, NSCLC, Pfizer, Xalkori, pharma

UK health watchdog NICE has given its approval for Roche’s selective ALK inhibitor Alecensa (alectinib) for use on the NHS, …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026